BPC-157 is one of the most aggressively enforced compounds on Meta. We have worked with eight clinics, four compounding pharmacies, and two research organizations that had BPC-157 ads rejected or accounts banned entirely. The compound is not FDA-approved for human use, and Meta flags any ad that mentions BPC-157 in the context of injury recovery, tissue repair, or gut health. Here is what we have learned about navigating these restrictions.
Why Meta Targets BPC-157 Specifically
Meta's proprietary enforcement system uses keyword matching and context analysis to flag peptides. BPC-157 triggers more restrictions than other research peptides because of the volume of claims made about it: accelerated healing, tendon repair, ligament recovery, digestive health benefits. These claims position BPC-157 as a therapeutic agent, which means Meta treats it as an unapproved drug under their Healthcare and Medicines policy.
The enforcement logic is straightforward. If your ad mentions BPC-157 AND an injury or health benefit, the ad is blocked. If BPC-157 appears in a research or compounding context without health claims, the ad may pass initial review but will likely be flagged in subsequent audits. Meta's automated system references FDA warning letters and enforcement actions against clinics promoting BPC-157 for unapproved uses.
The BAV Appeal Pathway
BAV (Beta-Adrenergic Vasopermeability) is not the appeal route. We see this mistake frequently. The BAV appeal pathway is specific to dietary supplements under DSHEA 1994. BPC-157 is not a dietary supplement. It is a research peptide, and the appeal pathway goes through Meta's Healthcare and Medicines policy, not the supplement policy.
The correct appeal strategy involves three layers. First, submit a policy clarification request explaining that your ad is for research purposes only, not therapeutic use. Second, include documentation of your research or compounding license if applicable. Third, modify your ad copy to remove any health claims and frame the product as a research peptide available for laboratory use only. We have had success with: "BPC-157 for research purposes. Not for human consumption. No medical claims implied."
Compounding Pharmacy Considerations
FDA 503A compounding pharmacies face the highest risk of account bans for BPC-157. The FDA has issued multiple warning letters to compounding pharmacies that advertise BPC-157 for therapeutic uses. In a 2023 FDA enforcement letter to a Florida compounding pharmacy, the agency cited the pharmacy for marketing BPC-157 as a treatment for "joint pain, ligament damage, and gastrointestinal issues" without FDA approval under Section 505(a) of the FDCA. Meta uses these FDA enforcement actions as reference material for their own enforcement decisions.
FDA 503B outsourcing facilities have stricter CGMP requirements but face similar advertising restrictions. Even if your BPC-157 is compounded in an FDA-registered 503B facility, Meta still treats any health claim as a violation. The difference is that 503B facilities can reference their FDA registration in their appeal to establish legitimacy. We have seen 503B facilities get ads approved by using language like: "FDA-registered 503B compounding facility. BPC-157 available for research. Contact us for COA and documentation."
Recovering a Banned BPC-157 Account
One of our clients, a compounding pharmacy in Arizona, had their entire Meta Business account restricted after running BPC-157 ads for three weeks. The ads were using language like: "BPC-157 supports natural healing and recovery" which Meta flagged as unapproved drug claims.
We rebuilt their ad library from scratch. Every new ad used this framework:
No health claims at all. The product described as "research peptide BPC-157" and nothing more.
Landing page stated: "For research and laboratory use only." COA (Certificate of Analysis) available on request.
No before-and-after imagery. No customer testimonials about results. The landing page focused entirely on product purity and documentation.
The appeal took 12 days. Meta reinstated the account with a warning about future compliance. The pharmacy now runs BPC-157 ads consistently with an acceptance rate above 80%. The key was removing every single implication of therapeutic benefit and positioning the product strictly as a research chemical.
Alternative Advertising Channels for BPC-157
If Meta continues to reject your BPC-157 ads, consider these alternative channels:
Google Ads allows research peptide advertising under their research chemicals policy, but you need to apply for the appropriate certification and ensure no health claims appear on your landing page.
PubMed and academic networks work well for research organizations targeting a scientific audience.
Email marketing to existing customers with research-level interest can bypass platform restrictions entirely.
LinkedIn has a more permissive approach to research peptides provided the content is educational rather than promotional. Posting about BPC-157 research studies from peer-reviewed journals typically passes LinkedIn's review process.
Documentation You Need for Appeals
When appealing a BPC-157 ad rejection on Meta, have these documents ready:
Your business license and state compounding registration. If you are a 503B facility, include your FDA establishment registration number.
Certificate of Analysis for your BPC-157 batch. This shows purity and confirms the product is laboratory grade.
A clear statement that the product is for research use only. This should appear on your landing page, your ad copy, and your checkout flow.
Your privacy policy and terms of service. These must show that you make no medical claims about BPC-157.
Download our compliance checklist for peptide advertising on Meta. It covers the exact language requirements, landing page requirements, and documentation checklist that we use for every BPC-157 client.
Ready to run BPC-157 ads on Meta without getting banned? Book a call at calendly.com/custodio-2/30min and we will audit your current setup in 30 minutes.